Stocktoria
Tectonic Therapeutic, Inc. TECX
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-06-21
Tectonic Therapeutic, Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $63.5M | $41.4M | $37.0M | $72.2M | $83.1M | $87.2M | $55.0M | $35.1M | $15.2M |
| Operating income | -$84.0M | -$58.0M | -$44.6M | -$105.4M | -$118.8M | -$120.2M | -$75.8M | -$46.2M | -$18.4M |
| Income tax | $1.2M | $0 | $0 | $0 | — | — | — | — | — |
| Net income | -$74.2M | -$58.0M | -$42.8M | -$105.9M | -$119.1M | -$119.7M | -$73.0M | -$46.4M | -$18.6M |
| EPS (diluted) | $-4.05 | $-6.83 | $-33.76 | $-2.42 | $-2.78 | — | — | — | — |
| Operating cash flow | -$60.1M | -$59.1M | -$40.7M | -$97.2M | -$98.0M | -$98.8M | -$67.7M | -$37.6M | -$16.4M |
| Free cash flow | -$60.3M | -$59.2M | -$41.0M | -$97.5M | -$100.5M | -$100.0M | -$69.3M | -$39.5M | -$16.8M |
| Cash & equivalents | $253.8M | $141.2M | $28.8M | $92.6M | $189.6M | $259.7M | $187.0M | $126.3M | $6.0M |
| Total assets | $261.0M | $152.9M | $39.4M | $103.9M | $203.8M | $271.2M | $200.5M | $133.5M | $7.0M |
| Total liabilities | $9.7M | $12.1M | $43.4M | $28.6M | $34.4M | $16.9M | $14.5M | $11.3M | $3.7M |
| Shareholders' equity | $251.3M | $140.8M | -$84.6M | -$45.7M | $169.5M | $254.3M | $186.0M | $122.2M | -$23.1M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.